-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Cabaletta Bio, Lowers Price Target to $8

Benzinga·11/09/2026 18:18:25
Listen to the news
Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $10 to $8.